BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $18.00 price objective on the stock. BriaCell Therapeutics Price Performance Shares of NASDAQ:BCTX opened at $1.44 on Friday. The […]
NASHVILLE, Tenn., May 23, 2024 /PRNewswire/ XLCS Partners, Inc., a leading middle-market investment bank, is pleased to announce it served as the exclusive advisor to SVI International (SVI) on
Presenter SpeechRajiv Jain Good afternoon to our U.S. stockholders, and good morning to our Australian CDI holders. We are pleased to welcome you all to our Annual Stockholder Meeting, which we re.